In addition, tamoxifen was used in most cases of premenopausal breast cancer, which might be attributed to Japanese insurance policies not allowing the concomitant use of LH-RH agonist and aromatase inhibitors. The gene discussed is CYP19A1; the disease is breast carcinoma.